The integration of robotics and the Internet of Things into the medical field has reached a critical juncture where the static algorithms of the past are being replaced by the fluid, creative potential of generative artificial intelligence. As we navigate this transition, James Maitland stands at the forefront of the conversation, bridging the gap between innovative engineering and the stringent requirements of healthcare policy. With extensive experience in implementing complex IoT systems within hospital infrastructures, Maitland has spent the last few years observing the Food and Drug Administration’s evolving stance on these “living” technologies. His perspective is shaped by a deep passion for how machine learning can move beyond simple data analysis to become an active, drafting partner for clinicians. In this discussion, we explore the nuances of the regulatory frameworks currently taking shape, the inherent risks of AI “hallucinations,” and the industry’s cautious dance around new oversight standards.
While traditional medical devices often have fixed outputs, generative AI is significantly more dynamic. How does this shift from static to generative outputs fundamentally change the way we must approach safety and efficacy testing?
The shift is nothing short of a paradigm change because we are moving away from the “black box” that always gives the same answer to a system that essentially thinks on its feet. In traditional medtech, you test a device against a thousand variables and if the output is consistent, you have a product, but generative AI introduces the risk of “hallucinations” where the system might confidently produce a radiology report that looks authentic but is factually incorrect. This unpredictability means that safety testing can no longer be a one-time event performed before the product hits the shelves; it must be an ongoing, longitudinal process. We are looking at a future where a model’s performance might actually degrade over time, a phenomenon that creates a sensory nightmare for regulators who are used to hardware that stays the same unless it physically breaks. The environmental costs and the sheer variety of possible outputs—ranging from synthesized images to conversational text—require us to build a monitoring net that is as wide and as flexible as the AI itself.
The FDA has authorized over 1,500 devices with AI components, yet generative AI-enabled devices remain in a different category regarding formal authorization. What does the current landscape look like for companies attempting to break into this regulated space?
Currently, the landscape is defined by a very deliberate, almost hesitant, exploration where no generative AI device has yet received full regulated authorization despite the massive number of traditional AI tools already on the market. We see high-profile players like Aidoc and a subsidiary of Radiology Partners receiving breakthrough designations for tools that interpret chest X-rays and draft reports, but these are still in the developmental pipeline rather than active clinical use. Another fascinating example is Modella AI’s PathChat, which utilizes generative capabilities to assist pathologists in diagnosing complex cases by analyzing clinical data and pathology images simultaneously. Even with these advancements, most companies are still operating in what I call the “regulatory periphery,” focusing on administrative tools or workflow stabilizers that don’t trigger the full weight of device regulations. It is a high-stakes game of “wait and see,” as firms watch for the final guidance to avoid becoming the proverbial guinea pig in a new and untested oversight regime.
The FDA’s recent discussion paper introduced the concept of a “competency-based assessment” for these devices. Could you elaborate on how this mimics the way we evaluate human medical professionals?
The FDA is essentially admitting that we can no longer “see completely under the hood” of these massive models, so they are treating the AI more like a medical student than a piece of hardware. Instead of inspecting every line of code, the agency is looking at benchmarking and supervision, much like how a resident is evaluated through exams and public reporting of their clinical outcomes. This approach acknowledges that the range of possible inputs and outputs for a generative model is simply too vast to test in a laboratory setting. By shifting the focus to competency, the regulator is looking for a “behavioral” track record—how the AI handles complex, real-world data and whether it can maintain a standard of care over a sustained period. It is a fascinating move toward a more holistic, almost clinical form of validation that prioritizes the quality of the “professional” output over the mechanical consistency of the underlying algorithm.
One of the proposed solutions for evaluating third-party models is the creation of “foundation model device master files.” How would this system resolve the tension between proprietary secrets and the need for regulatory transparency?
This concept is a direct carryover from the pharmaceutical world, where the manufacturer of a specific component—like a gel capsule—doesn’t want to reveal its secret recipe to every drug company that uses it. In our world, a medtech firm might build an amazing diagnostic tool on top of a third-party foundation model like ChatGPT or Claude, but they don’t actually own or understand the inner workings of that underlying engine. The master file would allow the model developer to submit their proprietary data directly and confidentially to the FDA, giving the regulator the “ingredients” they need to assess safety without exposing those secrets to the end-market developer. It creates a “trusted middleman” dynamic that is essential because, without it, the FDA would be flying blind regarding the most critical part of the device’s brain. This structure is intended to encourage innovation by protecting intellectual property while still giving the agency the necessary oversight to ensure the foundation isn’t fundamentally flawed.
There is a significant emphasis now on postmarket monitoring rather than relying solely on premarket authorization. What are the practical implications for healthcare institutions that have to manage these tools daily?
The shift toward accepting greater premarket uncertainty in exchange for rigorous postmarket monitoring places a heavy, and sometimes confusing, burden on both the vendors and the hospitals. We are seeing a call for healthcare institutions to vet these tools internally, but there is an ongoing debate about whose responsibility it is when a system’s performance begins to degrade six months after installation. Experts at institutions like the NYU Grossman School of Medicine have pointed out that while vendors should ideally ensure their products continue to work well, the reality is that monitoring standards are still looser than they should be. It requires a new kind of digital hygiene within hospitals, where clinical staff must be trained to spot AI drift and report it, much like they would report a malfunctioning surgical robot or a contaminated batch of medication. The agency will likely rely heavily on the companies themselves to provide frequent updates, which means the relationship between the regulator and the regulated will become a continuous, real-time conversation rather than a series of one-off approvals.
We are seeing a trend where companies use “wellness exemptions” to bypass traditional FDA review for generative AI features. How does this impact the safety of the average consumer?
This is where the line between a helpful health coach and a medical device becomes dangerously thin, as seen with firms like Dexcom adding generative AI to their over-the-counter glucose sensors. By framing these features as “personalized wellness recommendations” rather than diagnostic tools, companies can analyze user data and provide advice without the multi-year process of a premarket submission. While this speeds up the delivery of innovative features to the public, it also removes the safety net that ensures the advice given is clinically sound and free from the “hallucinations” we discussed earlier. It creates a two-tiered system: one where regulated devices undergo intense scrutiny, and another where “wellness” tools operate with far less oversight, often leaving the consumer to decide for themselves if the AI’s advice is trustworthy. This “dancing around the regulated space” is a strategy used by many to avoid being the first to test the FDA’s new generative AI frameworks, but it leaves a gap in the protection of public health.
The rise of unregulated chatbots for mental health has sparked intense debate among ethicists and clinicians. What specific risks do these “AI companions” pose when they are not marketed explicitly as medical devices?
The risk is incredibly high because people are already turning to these tools in moments of crisis, with nearly a quarter of large language model users reporting that they have used an LLM for mental health support. Some of these commercial chatbots go as far as falsely claiming to be therapists, which can lead to disastrous consequences if the AI provides harmful advice or fails to recognize a genuine emergency. Because these bots don’t currently fall under the FDA’s purview unless they are marketed for a specific medical purpose, they bypass the clinical evidence considerations that are standard for digital mental health devices. The HHS and the FDA’s device center are currently working on guidance for “digital mental health devices,” but the commercial, general-purpose chatbot remains a wild card. It is perhaps one of the most dangerous applications of generative AI because it leverages the technology’s ability to sound empathetic and authoritative without any underlying medical accountability or ethical guardrails.
Given the current trajectory of regulatory discussions and the rapid evolution of foundation models, what is your forecast for generative AI in the medical device sector?
My forecast is that from 2026 to 2028, we will see a “great convergence” where the FDA moves past discussion papers and begins to issue binding, specific guidance that forces these “wellness” and “administrative” tools into a more formal regulatory framework. We will likely see the first authorized generative AI diagnostic tools emerge from the breakthrough designation pipeline, particularly in radiology and pathology, where the outputs are more easily compared against ground-truth data. However, the tension between the push for faster AI adoption and the need for safety will only intensify, potentially leading to a more bifurcated market where “high-risk” generative tools are held to a physician-like competency standard while “low-risk” tools are managed through a lighter, postmarket-heavy approach. The success of programs like TEMPO, which allows for real-world data collection from participants like Limbic, will be the litmus test for whether we can truly balance innovation with the absolute necessity of patient safety. We are moving toward a future where the AI is not just a tool, but a supervised member of the clinical team, and our regulations are finally starting to reflect that reality.
